Xsphera Biosciences, is pleased to announce the formalization of a Memorandum of Understanding (MOU) with NEX-I, a Seoul-based pioneer in immune-oncology therapeutics.

Assays focus on accelerating cancer research.

Novel computational model accurately predicts significant irAEs in NSCLC patients based on proteomic profiling of one pre-treatment blood test.

Collaboration leverages two CDx assays from Thermo Fisher to support greater access to genomic testing for cancer patients in Japan and the United States.

Joint development collaboration to bring leading-edge nanopore sequencing into clinical laboratories at Mayo Clinic to increase understanding and improve treatment of cancer and genetic disorders.

Carcinotech and CELLINK plan to revolutionize the drug discovery market by leveraging CELLINK’s bioprinting solutions and Carcinotech’s expertise in producing 3D bioprinted living tumors to provide protocols for users to develop cutting-edge cancer models.

Corgenix, a Sebia Group company, CAP/CLIA clinical laboratory, positions Sebia to globally commercialize M-inSight®, a novel non-invasive liquid biopsy assay for Minimal Residual Disease (MRD) monitoring in multiple myeloma.

Curiox Biosystems announces its collaboration with Dr. Marco Ruella, an assistant professor of medicine at the Perelman School of Medicine, to support efforts in the development of next-generation cancer cell therapies.

Orano Med SAS, and Orbit Discovery Ltd, announced that they have entered into a collaboration to discover specific Peptide Receptor Radionuclide Therapies against cancer cells and advance the development of novel radiopharmaceuticals.

AMSBIO has supplied a custom monoclonal antibody (mAB) to researchers at the TU Dortmund** in Germany to unravel the role of EDI3 in breast cancer development.